AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29357293 — intervention group
Group type: COMPARATOR
Intervention: Sham mandibular advancement splint (MAS)
Number of subjects: 18
Study 27146667 — intervention group
Group type: EXPERIMENTAL
Intervention: SpeedCourt intervention (28 athletes)
Number of subjects: 50
Study 27146667 — intervention group
Group type: COMPARATOR
Intervention: Regular stabilization program (22 athletes)
Number of subjects: 50
Study 24748161 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery at hospitals with at least 500 beds
Number of subjects: 35946
Study 24748161 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery (general)
Number of subjects: 35946
Study 24748161 — intervention group
Group type: EXPERIMENTAL
Intervention: Emergency surgery
Number of subjects: 35946
Study 24748161 — intervention group
Group type: EXPERIMENTAL
Intervention: Census-tract poverty rate
Number of subjects: 35946
Study 24748161 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnosis of colon cancer (versus rectal cancer)
Number of subjects: 35946
Study 22704284 — intervention group
Group type: EXPERIMENTAL
Intervention: Norwood procedure
Number of subjects: 549
Study 20949133 — intervention group
Group type: EXPERIMENTAL
Intervention: Maraviroc
Number of subjects: 30
Study 20949133 — intervention group
Group type: COMPARATOR
Intervention: Efavirenz
Number of subjects: 30
Study 17065257 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalent meningococcal outer membrane vesicle vaccine (B:4:P1.19,15 and B:4:P1.7‐2,4)
Number of subjects: 321
Study 17065257 — intervention group
Group type: COMPARATOR
Intervention: Control group (two doses of hepatitis A and one of conjugated meningococcal serogroup C vaccine on a 0-1-6 month schedule)
Number of subjects: 321
Study 16263208 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary supplement (soy, isoflavones, lycopene, silymarin, antioxidants)
Number of subjects: 49
Study 11874927 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin Aspart (IAsp)
Number of subjects: 146
Study 11874927 — intervention group
Group type: COMPARATOR
Intervention: Buffered Regular Insulin (BR)
Number of subjects: 146
Study 11874927 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin Lispro
Number of subjects: 146
Study 10450255 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine add-on treatment
Number of subjects: 38
Study 10450255 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (no clozapine)
Number of subjects: 38
Study 7851193 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled-release mesalamine at 4 g/day for 12 months
Number of subjects: 205
Study 7851193 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 205
Study 2186351 — intervention group
Group type: EXPERIMENTAL
Intervention: Aztreonam (AZ) and Ampicillin (AMP)
Number of subjects: 147
Study 2186351 — intervention group
Group type: COMPARATOR
Intervention: Amikacin (AM) and Ampicillin (AMP)
Number of subjects: 147
Study 395525 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg danazol daily for 100 days
Number of subjects: 40
Study 395525 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 30577050 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipolar sealer
Number of subjects: 101
Study 30577050 — intervention group
Group type: COMPARATOR
Intervention: Conventional electrocautery
Number of subjects: 101
Study 30664457 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate access to Music eScape mobile app
Number of subjects: 169
Study 30664457 — intervention group
Group type: COMPARATOR
Intervention: Delayed access to Music eScape mobile app
Number of subjects: 169
Study 29107562 — intervention group
Group type: EXPERIMENTAL
Intervention: Dolutegravir monotherapy (50 mg once a day)
Number of subjects: 104
Study 29107562 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed switch to Dolutegravir monotherapy
Number of subjects: 104
Study 29107562 — intervention group
Group type: COMPARATOR
Intervention: Combination ART
Number of subjects: 104
Study 29107562 — intervention group
Group type: EXPERIMENTAL
Intervention: Dolutegravir monotherapy
Number of subjects: 104
Study 24858231 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 mg kg(‐1) dezocine (Group D)
Number of subjects: 108
Study 24858231 — intervention group
Group type: COMPARATOR
Intervention: Saline (Group S)
Number of subjects: 108
Study 23242974 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin
Number of subjects: 64
Study 23242974 — intervention group
Group type: COMPARATOR
Intervention: Dabigatran
Number of subjects: 64
Study 22156542 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) at 33 μg/kg/day
Number of subjects: 96
Study 22156542 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) at 67 μg/kg/day
Number of subjects: 96
Study 22156542 — intervention group
Group type: COMPARATOR
Intervention: Untreated control (UC) group at 33 μg/kg/day
Number of subjects: 96
Study 22156542 — intervention group
Group type: COMPARATOR
Intervention: Untreated control (UC) group at 67 μg/kg/day
Number of subjects: 96
Study 19188504 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning (IPC)
Number of subjects: 242
Study 19188504 — intervention group
Group type: COMPARATOR
Intervention: Control (uninflated cuff)
Number of subjects: 242
Study 17827633 — intervention group
Group type: COMPARATOR
Intervention: Initial antithrombin (AT) levels
Number of subjects: 54
Study 17827633 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial antithrombin (AT) levels at 15 mg/dL
Number of subjects: 54
Study 15155311 — intervention group
Group type: EXPERIMENTAL
Intervention: S(+)‐ketamine
Number of subjects: 106
Study 15155311 — intervention group
Group type: COMPARATOR
Intervention: remifentanil
Number of subjects: 106
Study 11354520 — intervention group
Group type: EXPERIMENTAL
Intervention: Competitive male cyclists (CG)
Number of subjects: 12
Study 11354520 — intervention group
Group type: COMPARATOR
Intervention: Sedentary men (SG)
Number of subjects: 12
Study 9891195 — intervention group
Group type: EXPERIMENTAL
Intervention: Ispaghula husk
Number of subjects: 394
Study 9891195 — intervention group
Group type: COMPARATOR
Intervention: Other laxatives (mainly lactulose)
Number of subjects: 394
Study 8022533 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 micrograms triiodothyronine (T3) administered orally for 3 consecutive days
Number of subjects: 14
Study 2684495 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal carbon dioxide removal (ECCO2R)
Number of subjects: 0
Study 2684495 — intervention group
Group type: COMPARATOR
Intervention: Conventional continuous positive pressure ventilation (CPPV)
Number of subjects: 0
Study 1096901 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen 500 mg daily
Number of subjects: 50
Study 1096901 — intervention group
Group type: COMPARATOR
Intervention: Indometacin 100 mg daily
Number of subjects: 50
Study 30273568 — intervention group
Group type: EXPERIMENTAL
Intervention: Off-pump CABG
Number of subjects: 835
Study 30273568 — intervention group
Group type: COMPARATOR
Intervention: On-pump CABG
Number of subjects: 835
Study 28203023 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular reconstruction of superficial femoral artery
Number of subjects: 36
Study 28203023 — intervention group
Group type: COMPARATOR
Intervention: Non-reconstruction group (control)
Number of subjects: 36
Study 23728804 — intervention group
Group type: EXPERIMENTAL
Intervention: Er:YAG laser
Number of subjects: 20
Study 23728804 — intervention group
Group type: COMPARATOR
Intervention: Scalpel
Number of subjects: 20
Study 23211335 — intervention group
Group type: EXPERIMENTAL
Intervention: Lanthanum carbonate
Number of subjects: 72
Study 23211335 — intervention group
Group type: COMPARATOR
Intervention: Calcium carbonate
Number of subjects: 72
Study 21672312 — intervention group
Group type: EXPERIMENTAL
Intervention: Modification of TEE probe placement protocol (Group II): Probe inserted after anaesthetic induction, removed after heart examination, reinserted before weaning from cardiopulmonary bypass, and removed immediately after examination.
Number of subjects: 200
Study 21672312 — intervention group
Group type: COMPARATOR
Intervention: Standard TEE probe placement protocol (Group I): Probe inserted after anaesthetic induction and remained in place until completion of surgery.
Number of subjects: 200
Study 19456248 — intervention group
Group type: EXPERIMENTAL
Intervention: AndGynFM ratio
Number of subjects: 122
Study 17875005 — intervention group
Group type: EXPERIMENTAL
Intervention: 270 microg/week of pegylated IFN‐alpha2a for 4 weeks followed by 180 microg/week for 8 weeks
Number of subjects: 116
Study 17875005 — intervention group
Group type: COMPARATOR
Intervention: 180 microg/week for 12 weeks
Number of subjects: 116
Study 12482562 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronized fenofibrate (200 mg once daily)
Number of subjects: 28
Study 12482562 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 10686469 — intervention group
Group type: EXPERIMENTAL
Intervention: Seropositive subjects
Number of subjects: 1156
Study 10686469 — intervention group
Group type: COMPARATOR
Intervention: Seronegative recruits
Number of subjects: 1156
Study 9175386 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam
Number of subjects: 11
Study 9175386 — intervention group
Group type: COMPARATOR
Intervention: Standard antidepressants
Number of subjects: 11
Study 8380266 — intervention group
Group type: EXPERIMENTAL
Intervention: Nedocromil sodium 4 mg, 4 times daily for 8 weeks
Number of subjects: 67
Study 8380266 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study 3298387 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous administration of bovine superoxide dismutase (SOD) at a dosage of 0.25 mg/kg
Number of subjects: 45
Study 3298387 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 45
Study 29193662 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic supplementation
Number of subjects: 60
Study 28031759 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation (NMES) at frequency of 35Hz combined with pulmonary rehabilitation (NMES+RP)
Number of subjects: 30
Study 28031759 — intervention group
Group type: COMPARATOR
Intervention: Pulmonary rehabilitation only (RP)
Number of subjects: 30
Study 24957950 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradermal vaccination (Intanza)
Number of subjects: 100
Study 24957950 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular vaccination (Vaxigrip)
Number of subjects: 100
Study 23301465 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive therapy (acupuncture, Chinese herbal medicine, rehabilitation)
Number of subjects: 240
Study 23301465 — intervention group
Group type: COMPARATOR
Intervention: Acupuncture
Number of subjects: 240
Study 23301465 — intervention group
Group type: COMPARATOR
Intervention: Rehabilitation
Number of subjects: 240
Study 23301465 — intervention group
Group type: COMPARATOR
Intervention: Chinese herbal medicine
Number of subjects: 240
Study 20540666 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 g daily EPA
Number of subjects: 0
Study 20540666 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 g daily DHA
Number of subjects: 0
Study 20540666 — intervention group
Group type: COMPARATOR
Intervention: Olive oil (control group)
Number of subjects: 0
Study 18560581 — intervention group
Group type: EXPERIMENTAL
Intervention: Circumcised men
Number of subjects: 1319
Study 18560581 — intervention group
Group type: COMPARATOR
Intervention: Uncircumcised men
Number of subjects: 1319
Study 15984577 — intervention group
Group type: EXPERIMENTAL
Intervention: Vital exhaustion (VE) present
Number of subjects: 0
Study 15984577 — intervention group
Group type: COMPARATOR
Intervention: No vital exhaustion (VE)
Number of subjects: 0
Study 12616128 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxandrolone 0.1 mg/kg twice a day (n = 7)
Number of subjects: 14
Study 12616128 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 7)
Number of subjects: 14
Study 12616128 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxandrolone
Number of subjects: 14
Study 10854812 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin 400 mg orally, qds for 10 days
Number of subjects: 10
Study 10854812 — intervention group
Group type: COMPARATOR
Intervention: Clarithromycin 500 mg orally, bd for 10 days
Number of subjects: 10
Study 9049766 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent pneumatic calf compression garments
Number of subjects: 50
Study 9049766 — intervention group
Group type: COMPARATOR
Intervention: Enoxaparin
Number of subjects: 50
Study 1846793 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensity measurement using modified Borg scale during exercise
Number of subjects: 10
Study 1846793 — intervention group
Group type: EXPERIMENTAL
Intervention: Distress measurement using modified Borg scale during exercise
Number of subjects: 10
Study 1846793 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation analysis between 'intensity' and minute ventilation
Number of subjects: 10
Study 1846793 — intervention group
Group type: EXPERIMENTAL
Intervention: Slope comparison of 'intensity' and 'distress' against minute ventilation
Number of subjects: 10
Study 1846793 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation analysis between 'intensity' and 'distress' within individuals
Number of subjects: 10
Study 6178250 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextran 70
Number of subjects: 100
Study 6178250 — intervention group
Group type: COMPARATOR
Intervention: Sulphated polysaccharide (PZ 68)
Number of subjects: 100
Study 30944029 — intervention group
Group type: EXPERIMENTAL
Intervention: CytoSorb® HA during CPB
Number of subjects: 30
Study 30944029 — intervention group
Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 30
Study 30117300 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxidectin (4 mg, 8 mg, 16 mg, 24 mg, or 36 mg)
Number of subjects: 60
Study 30117300 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 27258494 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term dual antiplatelet therapy (DAT) (>12 months)
Number of subjects: 1010
Study 27258494 — intervention group
Group type: COMPARATOR
Intervention: Short-term dual antiplatelet therapy (DAT) (<12 months)
Number of subjects: 1010
Study 27258494 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel therapy for >12 months
Number of subjects: 1010
Study 27258494 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel therapy for <12 months
Number of subjects: 1010
Study 27258494 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term DAT
Number of subjects: 1010
Study 25532604 — intervention group
Group type: EXPERIMENTAL
Intervention: TVT Secur
Number of subjects: 74
Study 25532604 — intervention group
Group type: COMPARATOR
Intervention: TVT
Number of subjects: 74
Study 22034545 — intervention group
Group type: EXPERIMENTAL
Intervention: Case-based e-learning
Number of subjects: 141
Study 22034545 — intervention group
Group type: COMPARATOR
Intervention: Text-based learning
Number of subjects: 141
Study 21134043 — intervention group
Group type: EXPERIMENTAL
Intervention: RT001 Botulinum Toxin Type A Topical Gel
Number of subjects: 36
Study 21134043 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 17646515 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine with clonidine 1 microg/kg
Number of subjects: 83
Study 17646515 — intervention group
Group type: COMPARATOR
Intervention: Plain bupivacaine
Number of subjects: 83
Study 15767827 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxymorphone extended release (ER) 20 mg every 12 hours
Number of subjects: 153
Study 15767827 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxymorphone extended release (ER)
Number of subjects: 153
Study 12852712 — intervention group
Group type: EXPERIMENTAL
Intervention: IV linezolid 600 mg every 12 hours for 7 to 21 days
Number of subjects: 623
Study 12852712 — intervention group
Group type: COMPARATOR
Intervention: IV vancomycin 1 g every 12 hours for 7 to 21 days
Number of subjects: 623
Study 10380587 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyurea (alone or combined with interferon)
Number of subjects: 141
Study 10380587 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic stem cell transplantation
Number of subjects: 141
Study 10380587 — intervention group
Group type: COMPARATOR
Intervention: Control group (patients older than 55 years)
Number of subjects: 141
Study 10380587 — intervention group
Group type: COMPARATOR
Intervention: Control group (patients younger than 55 years)
Number of subjects: 141
Study 8853535 — intervention group
Group type: EXPERIMENTAL
Intervention: Palliative thoracic radiotherapy (external beam radiation)
Number of subjects: 0
Study 8853535 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined modality therapy (radiation and chemotherapy)
Number of subjects: 0
Study 8853535 — intervention group
Group type: COMPARATOR
Intervention: Five fractions of radiation
Number of subjects: 0
Study 8853535 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined chemotherapy and low-dose radiation protocol
Number of subjects: 0
Study 1745488 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose metoclopramide, dexamethasone, and lorazepam (MDL)
Number of subjects: 145
Study 1745488 — intervention group
Group type: COMPARATOR
Intervention: High-dose alizapride, dexamethasone, and lorazepam (ADL)
Number of subjects: 145
Study 1745488 — intervention group
Group type: EXPERIMENTAL
Intervention: MDL
Number of subjects: 145
Study 1745488 — intervention group
Group type: COMPARATOR
Intervention: ADL
Number of subjects: 145
Study 6293334 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. ranitidine 50 mg
Number of subjects: 12
Study 6293334 — intervention group
Group type: COMPARATOR
Intervention: 0.9% saline (control)
Number of subjects: 12
Study 31492050 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (6 mg·kg‐1)
Number of subjects: 8
Study 29237487 — intervention group
Group type: EXPERIMENTAL
Intervention: Graduated transition and organized support group intervention
Number of subjects: 216
Study 29237487 — intervention group
Group type: COMPARATOR
Intervention: Usual practice of abrupt transfer
Number of subjects: 216
Study 25119512 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal cord stimulation (SCS) activated
Number of subjects: 14
Study 25119512 — intervention group
Group type: COMPARATOR
Intervention: Spinal cord stimulation (SCS) deactivated
Number of subjects: 14
Study 25117929 — intervention group
Group type: EXPERIMENTAL
Intervention: Abacavir/Lamivudine (ABC/3TC)
Number of subjects: 245
Study 25117929 — intervention group
Group type: COMPARATOR
Intervention: Tenofovir/Emtricitabine (TDF/FTC)
Number of subjects: 245
Study 22298600 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy drink (Red Bull Energy Drink, 80 mg caffeine, 1000 mg taurine in 8.3 oz serving)
Number of subjects: 9
Study 22298600 — intervention group
Group type: COMPARATOR
Intervention: Caffeine supplementation (compounded caffeine solution, 80 mg caffeine in 8 oz bottled water)
Number of subjects: 9
Study 19187525 — intervention group
Group type: EXPERIMENTAL
Intervention: Field mosquitoes (human odour)
Number of subjects: 2
Study 19187525 — intervention group
Group type: EXPERIMENTAL
Intervention: Laboratory mosquitoes (human odour)
Number of subjects: 2
Study 19187525 — intervention group
Group type: COMPARATOR
Intervention: CO2 effect
Number of subjects: 2
Study 18082528 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-dimensional handheld ultrasound device
Number of subjects: 146
Study 18082528 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound volume scanner
Number of subjects: 146
Study 10890582 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized normal meal
Number of subjects: 12
Study 10890582 — intervention group
Group type: EXPERIMENTAL
Intervention: High fat diet
Number of subjects: 12
Study 10890582 — intervention group
Group type: EXPERIMENTAL
Intervention: High fat/high protein diet
Number of subjects: 12
Study 10890582 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting
Number of subjects: 12
Study 8813254 — intervention group
Group type: EXPERIMENTAL
Intervention: Elective lymph node dissection (ELND)
Number of subjects: 740
Study 8813254 — intervention group
Group type: COMPARATOR
Intervention: Nodal observation
Number of subjects: 740
Study 1318391 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate (B) ingestion
Number of subjects: 7
Study 1318391 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P) ingestion
Number of subjects: 7
Study 1318391 — intervention group
Group type: COMPARATOR
Intervention: Control (C - no ingestion)
Number of subjects: 7
Study 3909471 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid 500 mg + codeine phosphate 30 mg
Number of subjects: 129
Study 3909471 — intervention group
Group type: COMPARATOR
Intervention: Acetylsalicylic acid 500 mg
Number of subjects: 129
Study 29049268 — intervention group
Group type: EXPERIMENTAL
Intervention: Providence Pedi Cast-Sling (PPCS)
Number of subjects: 100
Study 29049268 — intervention group
Group type: COMPARATOR
Intervention: Standard sling
Number of subjects: 100
Study 29920745 — intervention group
Group type: EXPERIMENTAL
Intervention: Avatar-based education plus usual care
Number of subjects: 88
Study 29920745 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 88
Study 27255456 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroalcoholic extract of Tribulus terrestris (1000 mg/d)
Number of subjects: 98
Study 27255456 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98
Study 22789657 — intervention group
Group type: EXPERIMENTAL
Intervention: Online cognitive behavior therapy (CBT) with minimal therapist contact
Number of subjects: 205
Study 22789657 — intervention group
Group type: COMPARATOR
Intervention: Clinic delivery of CBT
Number of subjects: 205
Study 22789657 — intervention group
Group type: EXPERIMENTAL
Intervention: Online CBT with brief weekly emails and a single phone call
Number of subjects: 205
Study 22789657 — intervention group
Group type: EXPERIMENTAL
Intervention: Working alliance
Number of subjects: 205
Study 20421463 — intervention group
Group type: EXPERIMENTAL
Intervention: ALN‐RSV01
Number of subjects: 88
Study 20421463 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 88
Study 18947350 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparative judgments (e.g., indicating preference between two stimuli in different domains, comparing wild animals, comparing animals' physical attributes, estimating similarity between objects)
Number of subjects: 0